Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
GlaxoSmithKline ( (GB:GSK) ) has shared an announcement.
GSK plc has announced its total voting rights and capital as of October 31, 2025, in compliance with the Financial Conduct Authority’s rules. The company reported an issued share capital of over 4.3 billion shares, with a total of 4,060,655,255 voting rights available. This information is crucial for shareholders to determine their notification obligations regarding changes in their interest in the company.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £14.50 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GB:GSK Stock
According to Spark, TipRanks’ AI Analyst, GB:GSK is a Outperform.
GlaxoSmithKline’s strong financial performance and positive earnings call sentiment are the most significant factors driving the stock score. The company’s robust growth in specialty medicines and successful R&D efforts contribute positively. Technical analysis supports a bullish outlook, while valuation remains reasonable with an attractive dividend yield. Challenges in the U.S. vaccines market and clinical trial delays are noted but do not significantly detract from the overall positive outlook.
To see Spark’s full report on GB:GSK stock, click here.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) is a global healthcare company operating in the pharmaceutical industry, primarily focusing on the development and distribution of medicines, vaccines, and consumer healthcare products.
Average Trading Volume: 8,074,501
Technical Sentiment Signal: Buy
Current Market Cap: £71.54B
See more insights into GSK stock on TipRanks’ Stock Analysis page.